Anti-inflammatory drugs and their mechanism of action

Inflammation Research

Volumn 47, Issue SUPPL. 2, 1998, Pages

  Vane, J R ^a   Botting, R M ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Anti inflammatory drugs; Cyclooxygenase 1 (COX 1); Cyclooxygenase 2 (COX 2); Mechanism; Nonsteroidal anti inflammatory drugs (NSAIDS); Therapeutic use

Indexed keywords

ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ISOENZYME; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; COLON CANCER; CONFERENCE PAPER; DRUG MECHANISM; DRUG SELECTIVITY; GASTROINTESTINAL SYMPTOM; HUMAN; LABOR; NEPHROTOXICITY; OVULATION;

EID: 0031787631     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050284     Document Type: Conference Paper

References (113)

1. Stone E. An account of the success of the bark of the willow in the cure of agues. Philosophical Transactions of the Royal Society 1763;53:195-200.
2. Dreser H. Pharmakologisches über Aspirin (Acetylsalicylsäure). Pflügers Arch 1899;76:306-18.
3. Flower RJ. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev 1974;26:33-67.
4. Vane JR. The use of isolated organs for detecting active substances in the circulating blood. Br J Pharmacol Chemother 1964;23:360-73.
5. Piper PJ, Vane JR. The release of prostaglandins during anaphylaxis in guinea-pig isolated lungs. In: Mantegazza P, Horton EW, editors. Prostaglandins, Peptides and Amines. London/New York: Academic Press, 1969:15-9.
6. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975;72:2994-8.
7. Palmer MA, Piper PJ, Vane JR. The release of RCS from chopped lung and its antagonism by anti-inflammatory drugs. Br J Pharmacol 1970;40:581P.
8. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971;231:232-5.
9. Smith JH, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nature 1971;231:235-7.
10. Ferreira SH, Moncada S, Vane JR. Indomethacin and aspirin abolish prostaglandin release from spleen. Nature 1971;231:237-9.
11. Flower RJ, Vane JR. Inhibition of prostaglandin biosynthesis. Biochem Pharmacol 1974;23:1439-50.
12. Higgs GA, Moncada S, Vane JR. Eicosanoids in inflammation. Ann Clin Res 1984;16:287-99.
13. Vane JR, Botting RM. The mode of action of anti-inflammatory drugs. Postgrad Med J 1990;66(Suppl 4):S2-17.
14. Hemler M, Lands WEM, Smith WL. Purification of the cyclooxygenase that forms prostaglandins. Demonstration of the two forms of iron in the holoenzyme. J Biol Chem 1976; 251:5575-9.
15. DeWitt DL, Smith WL. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA 1988;85:1412-6.
16. Merlie JP, Fagan D, Mudd J, Needleman P. Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase). J Biol Chem 1988;263:3550-3.
17. Yokoyama C, Takai T, Tanabe T. Primary structure of sheep prostaglandin endoperoxide synthase deduced from cDNA sequence. FEBS Lett 1988;231:347-51.
18. Smith WL. Prostaglandin biosynthesis and its compartmentation in vascular smooth muscle and endothelial cells. Ann Rev Physiol 1986;48:251-62.
19. 2 synthase-1. Nature 1994;367:243-9.
20. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthetase by aspirin. Proc Natl Acad Sci USA 1975;72: 3073-6.
21. Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner MF. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol 1996;3:927-33.
22. 523 to Val mutation. J Biol Chem 1997;272:9280-6.
23. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976;263:663-5.
24. Whittle BJR, Higgs GA, Eakins KE, Moncada S, Vane JR. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature 1980;284:271-3.
25. Xie W, Robertson DL, Simmons DL. Mitogen-inducible prostaglandin G/H synthase: A new target for nonsteroidal antiinflammatory drugs. Drug Dev Res 1992;25:249-65.
26. 2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990; 265:16737-40.
27. Masferrer JL, Zweifel BS, Seibert K, Needleman P. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 1990;86:1375-9.
28. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991;88:2692-6.
29. O'Banion MK, Sadowski HB, Winn V, Young DA. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 1991;266:23261-7.
30. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/ cyclooxygenase homologue. J Biol Chem 1991;266:12866-72.
31. Sirois J, Richards JS. Purification and characterisation of a novel, distinct isoform of prostaglandin endoperoxide synthase induced by human chorionic gonadotropin in granulosa cells of rat preovulatory follicles. J Biol Chem 1992;267:6382-8.
32. Weissmann G. Prostaglandins as modulators rather than mediators of inflammation. J Lipid Mediat 1993;6:275-86.
33. Weissmann G. Aspirin. Sci Am 1991;January:84-90.
34. Wu KK, Sanduja R, Tsai AL, Ferhanoglu B, Loose-Mitchell DS. Aspirin inhibits interleukin-1-induced prostaglandin H synthase expression in cultured endothelial cells. Proc Natl Acad Sci USA 1991;88:2384-7.
35. Clissold SP. Paracetamol and phenacetin. Drugs 1986;32(Suppl 4):46-59.
36. Flower RJ, Vane JR. Inhibition of prostaglandin synthetase in brain explains the antipyretic activity of paracetamol (4-acetamidophenol). Nature 1972;240:410-1.
37. Whittle BJR, Vane JR. Prostanoids as regulators of gastrointestinal function. In: Johnston LR, editor. Physiology of the Gastrointestinal Tract, Vol. 1. 2nd ed. New York: Raven Press, 1987:143-80.
38. Kargman S, Charleson S, Cartwright M, Frank J, Riendeau D, Mancini J, et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey and human gastrointestinal tracts. Gastroenterology 1996;111:445-54.
39. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994;94:2504-10.
40. Yamagata K, Andreassson KI, Kaufman WE, Barnes CA, Worley PF. Expression of a mitogen-inducible cyclooxygenase in brain neurons; regulation by synaptic activity and glucocorlicoids. Neuron 1993;11:371-86.
41. Breder CD, Dewitt D, Kraig RP. Characterization of inducible cyclooxygenase in rat brain. J Comp Neurol 1995;355:296-315.
42. Breder CD, Saper CB. Expression of inducible cyclooxygenase mRNA in the mouse brain after systemic administration of bacterial lipopolysaccharide. Brain Res 1996;713:64-9.
43. Cao C, Matsumura K, Yamagata K, Watanabe Y. Endothelial cells of the brain vasculature express cyclooxygenase-2 mRNA in response to systemic interleukin-1β: A possible site of prostaglandin synthesis responsible for fever. Brain Res 1996; 733:263-72.
44. Cao C, Matsumura K, Yamagata K, Watanabe Y. Induction by lipopolysaccharide of cyclooxygenase-2 mRNA in rat brain: Its possible role in the febrile response. Brain Res 1995;697:187-96.
45. Marcheselli VL, Bazan NG. Sustained induction of prostaglandin endoperoxide synthase-2 by seizures in hippocampus. J Biol Chem 1996;271:24794-9.
46. Beiche F, Scheuerer S, Brune K, Geisslinger G, Goppelt-Struebe M. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett 1996;390:165-9.
47. Futaki N, Yoshikawa K, Hamasaka Y, Arai I, Higuchi S, Iizuka H, et al. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects which causes minimal stomach lesions. Gen Pharmacol 1993;24:105-10.
48. Tomlinson A, Appleton I, Moore AR, Gilroy DW, Willis D, Mitchell JA, Willoughby DA. Cyclo-oxygenase and nitric oxide synthase isoforms in rat carrageenin-induced pleurisy. Br J Pharmacol 1994;113:693-4.
49. Hatanaka K, Harada Y, Kawamura M, Ogino M, Saito M, Katori M. Cell types expressing COX-2 in rat carrageenin-induced pleurisy. Jpn J Pharmacol 1996;71(Suppl I):304P.
50. O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993;330:156-60.
51. Asano K, Lilly CM, Drazen JM. Prostaglandin G/H synthase-2 is the constitutive and dominant isoform in cultured human lung epithelial cells. Am J Physiol 1996;271:L126-31.
52. Walenga RW, Kester M, Coroneos E, Butcher S, Dwivedi R, Statt C. Constitutive expression of prostaglandin endoperoxide G/H synthase (PGHS)-2 but not PGHS-1 in human tracheal epithelial cells in vitro. Prostaglandins 1996;52:341-59.
53. Samet JM, Reed W, Ghio AJ, Devlin RB, Carter JD, Dailey LA, et al. Induction of prostaglandin H synthase 2 in human airway epithelial cells exposed to residual oil fly ash. Toxicol Appl Pharmacol 1996;141:159-68.
54. Bennett P, Slater D. COX-2 expression in labor. In: Vane J, Botting J, Botting R, editors. Improved Non-steroid Anti-inflammatory Drugs. COX-2 Enzyme Inhibitors. Lancaster, London: Kluwer Academic Publishers and William Harvey Press, 1996:167-88.
55. Gibb W, Sun M. Localization of prostaglandin H synthase type 2 protein and mRNA in term human fetal membranes and decidua. J Endocrinol 1996;150:497-503.
56. Trautman MS, Edwin SS, Collmer D, Dudley DJ, Simmons D, Mitchell MD. Prostaglandin H synthase-2 in human gestational tissues: Regulation in amnion. Placenta 1996;17:239-45.
57. Toth P, Li X, Lei ZM, Rao CV. Expression of human chorionic gonadotropin (hCG)/luteinizing hormone receptors and regulation of the cyclooxygenase-1 gene by exogenous hCG in human fetal membranes. J Clin Endocrinol Metab 1996;81:1283-8.
58. Zakar T, Hirst JJ, Milovic JE, Olson DM. Glucocorticoids stimulate the expression of prostaglandin endoperoxide H synthase-2 in amnion cells. Endocrinology 1995;136:1610-9.
59. Spaziani EP, Lantz ME, Benoit RR, O'Brien WF. The induction of cyclooxygenase-2 (COX-2) in intact human amnion tissue by interleukin-4. Prostaglandins 1996;51:215-23.
60. Chakraborty I, Das SK, Wang J, Dey SK. Developmental expression of the cyclo-oxygenase-1 and cyclo-oxygenase-2 genes in the peri-implantation mouse uterus and their differential regulation by the blastocyst and ovarian steroids. J Mol Endocrinol 1996; 16:107-22.
61. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995;83:483-92.
62. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumano N, Jenette JC, et al. Prostaglandin synthase 2 gene disruption causes renal pathology in the mouse. Cell 1995;83: 473-82.
63. Dinchuck JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995; 378:406-9.
64. Whittle BJR. Neuronal and endothelium-derived mediators in the modulation of the gastric microcirculation: integrity in the balance. Br J Pharmacol 1993;110:3-17.
65. Rainsford KD, Willis C. Relationship of gastric mucosal damage induced in pigs by antiinflammatory drugs to their effects on prostaglandin production. Dig Dis Sci 1982;27:624-35.
66. Chen XS, Sheller JR, Johnson EN, Funk CD. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature 1994;372:179-82.
67. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993;90;11693-7.
68. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993;268:6610-4.
69. Lanza FL. A review of gastric ulcer and gastroduodenal injury in normal volunteers receiving aspirin and other non-steroidal anti-inflammatory drugs. Scand J Gastroenterol 1989;24(Suppl 163): 24-31.
70. Akarasereenont P, Mitchell JA, Thiemermann C, Vane JR. Relative potency of nonsteroid anti-inflammatory drugs as inhibitors of cyclooxygenase-1 or cyclooxygenase-2. Br J Pharmacol 1994; 112(Suppl.):183P.
71. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-72.
72. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995;44:1-10.
73. Churchill L, Graham A, Shih C-K, Pauletti D, Farina PR, Grob PM. Selective inhibition of human cyclooxygenase-2 by meloxicam. Inflammopharmacology 1996;4;125-35.
74. Barner A. Review of clinical trials and benefit/risk ratio of meloxicam. Scand J Rheumatol 1996;25(Suppl 102):29-37.
75. Distel M, Mueller C, Bluhmki E, Fries J. Safety of meloxicam: A global analysis of clinical trials. Br J Rheumatol 1996;35(Suppl 1):68-77.
76. Tavares IA, Bishai PM, Bennet A. Activity of nimesulide on constitutive and inducible cyclooxygenases. Arzneimittelforschung/Drug Res 1995;45:1093-5.
77. Partrignani P, Panara MR, Santini G, Sciulli MG, Padovano R, Cipollone F. Differential inhibition of cyclooxygenase activity of prostaglandin endoperoxide synthase isozymes in vitro and ex vivo in man. Prostaglandins Leukot Essent Fatty Acids 1996;55(Suppl 1):P115.
78. Glaser K. Cyclooxygenase selectivity and NSAIDs: cyclooxygenase-2 selectivity of etodolac (Lodine). Inflammopharmacology 1995;3:335-45.
79. Brideau C, Kargman S, Liu S, Dallob AL, Ehrich EW, Rodger IW, et al. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 1996;45:68-74.
80. Prasit P. New highly selective COX-2 inhibitors. William Harvey Research Conference: Selective COX-2 Inhibitors. Phuket, Sept 17-19, 1997.
81. Weissenbach R. Clinical trials with nimesulide, a new non-steroid anti-inflammatory agent, in rheumatic pathology. J Int Med Res 1981;13:237-45.
82. Pais JM, Rosteiro FM. Nimesulide in the short-term treatment of the inflammatory process of dental tissues: a double-blind controlled trial against oxyphenbutazone. J Int Med Res 1983; 11:149-54.
83. Emami Nouri E. Nimesulide for treatment of acute inflammation of the upper respiratory tract. Clin Ther 1984;6:142-50.
84. Fusetti G, Magni E, Armandola MC. Tolerability of nimesulide. Epidemiological data. Drugs 1993;46(Suppl 1):277-80.
85. Senna GE, Passalacqua G, Andri G, Dama AR, Albano M, Fregonese L, et al. Nimesulide in the treatment of patients intolerant of aspirin and other NSAIDs. Drug Saf 1996;14:94-103.
86. Glaser K, Sung M-L, O'Neill K, Belfast M, Hartman D, Carlson R, et al. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol 1995;281:107-11.
87. Laine L, Sloane R, Ferretti M, Cominelli F. A randomized double-blind comparison of placebo, etodolac and naproxen on gastrointestinal injury and prostaglandin production. Gastrointest Endosc 1995;42:428-33.
88. Cummings DM, Amadio P Jr. A review of selected newer nonsteroidal anti-inflammatory drugs. Am Fam Physician 1994;49:1197-202.
89. Isakson P, Zweifel B, Masferrer J, Koboldt C, Seibert K, Hubbard R, et al. Specific COX-2 inhibitors: From bench to bedside. In: Vane J, Botting J, editors. Selective COX-2 Inhibitors. Pharmacology, Clinical Effects and Therapeutic Potential. London: Kluwer Academic Publishers and William Harvey Press, 1998:1-17.
90. Hubbard RC, Mehlisch DR, Jasper DR, Nugent MJ, Yu S, Isakson PC. SC-58635, a highly selective inhibitor of COX-2, is an effective analgesic in an acute post-surgical pain model. J Invest Med 1996;44:293A.
91. Lanza FL, Rack MF, Callison DA, Hubbard RC, Yu SS, Talwalker S, et al. A pilot endoscopic study of the gastroduodenal effects of SC-58635, a novel COX-2 selective inhibitor [abstract]. Gastroenterology 1997;112:A194.
92. Ford-Hutchinson AW. New highly selective COX-2 inhibitors. In: Vane J, Botting J, editors. Selective COX-2 Inhibitors. Pharmacology, Clinical Effects and Therapeutic Potential. London: Kluwer Academic Publishers and William Harvey Press, 1998:117-25.
93. Lanza F, Simon T, Quan H, Bolognese J, Rack MF, Hoover M, et al. Selective inhibition of cyclooxygenase-2 (COX-2) with MK-0966 (250 mg q.d.) is associated with less gastroduodenal damage than aspirin (ASA) 650 mg q.i.d. or ibuprofen (IBU) 800 mg t.i.d. [abstract]. Gastroenterology 1997;112:A194.
94. Ehrich E, Mehlisch D, Perkins S, Brown P, Willreich J, Lipschutz K, et al. Efficacy of MK-966, a highly selective inhibitor of COX-2, in the treatment of postoperative denial pain [abstract]. Arthritis Rheum 1996;39(Suppl 9): S81.
95. Sawdy R, Slater D, Fisk N, Edmonds DK, Bennett P. Use of a cyclo-oxygenase type-2-selective non-steroidal anti-inflammatory agent to prevent preterm delivery. Lancet 1997;350:265-6.
96. Gibb W, Sun M. Localization of prostaglandin H synthase type 2 protein and mRNA in term human fetal membranes and decidua. J Endocrinol 1996;150:497-503.
97. Thun MJ, Namboodiri MM, Heath CWJ. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325: 1593-6.
98. Luk GD. Prevention of gastrointestinal cancer - the potential role of NSAIDs in colorectal cancer. Schweiz Med Wochenschr 1996;126:801-12.
99. Nugent KP, Spigelman AD, Phillips RKS. Tissue prostaglandin levels in familial adenomatous polyposis patients treated with sulindac. Dis Colon Rectum 1996;39:659-62.
100. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hyland LM, Celano P, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-6.
101. Matsuhashi N, Nakajima A, Fukushima Y, Yazaki Y, Oka T. Effects of sulindac on sporadic colorectal adenomatous polyps. Gut 1997;40:344-9.
102. Kutchera W, Jones DA, Matsunami N, Groden J, McIntyre TM, Zimmerman GA, et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: Evidence for a transcriptional effect. Proc Natl Acad Sci USA 1996;93:4816-20.
103. Gustafson-Svärd C, Lilja I, Hallböök O, Sjödahl R. Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats. Gut 1996;38:79-84.
104. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;104:1183-8.
105. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997;99:2254-9.
106. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9.
107. Cochran FR, Vitek MP. Neuroinflammatory mechanisms in Alzheimer's disease: New opportunities for drug discovery. Expert Opin Invest Drugs 1996;5:449-55.
108. Breitner JCS, The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Ann Rev Med 1996;47:401-11.
109. McGeer PL, McGeer EG. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 1995;21:195-218.
110. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997;48:626-32.
111. Hampel H, Muller N. Inflammatory and immunological mechanisms in Alzheimer's disease. Drug News Perspect 1995;8:599-608.
112. Yan SD, Zhu H, Fu J, Yan SF, Roher A, Tourtellotte WW, et al. Amyloid-β peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: A proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci USA 1997;94:5296-301.
113. Chang JW, Coleman PD, O'Banion MK. Prostaglandin G/H synthase-2 (cyclooxygenase-2) mRNA expression is decreased in Alzheimer's disease. Neurobiol Aging 1996;17:801-8.